Fiduciary Family Office LLC Purchases 2,241 Shares of STERIS plc $STE

Fiduciary Family Office LLC boosted its position in STERIS plc (NYSE:STE) by 78.8% in the 2nd quarter, Holdings Channel reports. The firm owned 5,085 shares of the medical equipment provider’s stock after buying an additional 2,241 shares during the quarter. Fiduciary Family Office LLC’s holdings in STERIS were worth $1,221,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Foresight Group Ltd Liability Partnership bought a new stake in STERIS in the first quarter worth about $25,958,000. Ascent Group LLC bought a new stake in STERIS in the first quarter worth about $261,000. Allianz Asset Management GmbH lifted its stake in STERIS by 31.9% in the first quarter. Allianz Asset Management GmbH now owns 102,488 shares of the medical equipment provider’s stock worth $23,229,000 after purchasing an additional 24,809 shares during the last quarter. Golden State Wealth Management LLC lifted its stake in STERIS by 503.0% in the first quarter. Golden State Wealth Management LLC now owns 199 shares of the medical equipment provider’s stock worth $45,000 after purchasing an additional 166 shares during the last quarter. Finally, Vontobel Holding Ltd. lifted its stake in STERIS by 17.1% in the first quarter. Vontobel Holding Ltd. now owns 2,071 shares of the medical equipment provider’s stock worth $469,000 after purchasing an additional 302 shares during the last quarter. Institutional investors own 94.69% of the company’s stock.

STERIS Stock Performance

Shares of STE stock opened at $242.34 on Tuesday. The firm has a market cap of $23.87 billion, a price-to-earnings ratio of 37.11 and a beta of 1.01. The company’s 50 day moving average is $245.10 and its 200 day moving average is $236.64. The company has a quick ratio of 1.53, a current ratio of 2.22 and a debt-to-equity ratio of 0.27. STERIS plc has a 52-week low of $200.98 and a 52-week high of $253.00.

STERIS (NYSE:STE) last issued its quarterly earnings data on Wednesday, August 6th. The medical equipment provider reported $2.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.02. The company had revenue of $1.40 billion for the quarter, compared to analyst estimates of $1.36 billion. STERIS had a net margin of 11.61% and a return on equity of 14.17%. STERIS’s revenue was up 8.8% compared to the same quarter last year. During the same period last year, the company posted $2.03 earnings per share. On average, sell-side analysts anticipate that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 26th. Investors of record on Thursday, September 4th were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, September 4th. This is a positive change from STERIS’s previous quarterly dividend of $0.57. This represents a $2.52 annualized dividend and a yield of 1.0%. STERIS’s dividend payout ratio is 38.59%.

Insider Activity at STERIS

In related news, CEO Daniel A. Carestio sold 159 shares of STERIS stock in a transaction that occurred on Monday, October 6th. The shares were sold at an average price of $241.82, for a total transaction of $38,449.38. Following the transaction, the chief executive officer directly owned 51,096 shares of the company’s stock, valued at $12,356,034.72. This trade represents a 0.31% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, VP Renato Tamaro sold 3,204 shares of STERIS stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $249.24, for a total transaction of $798,564.96. Following the transaction, the vice president directly owned 7,221 shares in the company, valued at approximately $1,799,762.04. The trade was a 30.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 18,868 shares of company stock valued at $4,585,389 over the last quarter. 1.07% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on STE shares. KeyCorp raised their target price on shares of STERIS from $277.00 to $288.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 22nd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research report on Tuesday, October 14th. Morgan Stanley raised their target price on shares of STERIS from $276.00 to $295.00 and gave the stock an “overweight” rating in a research report on Friday, August 8th. Finally, Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 14th. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $273.50.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.